<DOC>
	<DOCNO>NCT01231464</DOCNO>
	<brief_summary>The objective study compare efficacy safety Fluticasone Furoate Nasal Spray ( FFNS ) , FFNS placebo Chinese adult adolescent subject Allergic Rhinitis AR . There 3 phase , 2 to14 day run , 2 week treatment , 3 5 day follow . After run period , least 360 subject AR ( age 12yrs 65yrs , inclusive ) randomise receive FFNS 110ug daily placebo 2 week . The primary endpoint change baseline reflective total nasal symptom score ( rTNSS ) treatment period , secondary endpoint include mean change baseline nasal find score rhinoscopy completion study treatment , severity overall inference activity daily live . Safety measure include AE ( Adverse Event ) report , ECGs ( Electrocardiograph ) , physical exam , vital sign , nasal exam . In addition , reflective total ocular symptom score ( rTOSS ) measure explorative endpoint , specific AR ( Allergic Rhinitis ) patient severe ocular symptom .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Evaluate Efficacy Safety Fluticasone Furoate Nasal Spray 2 Weeks Chinese Adult Adolescent Subjects With Allergic Rhinitis</brief_title>
	<detailed_description>This multicenter , 2 week , double blind , randomize , placebo control trial . 7 investigational site enlist randomize least 360 subject ( outpatient ) 2009 2010 . Throughout entire study period , antiallergy drug rhinitis medication , include rescue medication symptom relief anti-hyperactivity allow . The run period consist minimum 2 day maximum 14 day . During period , intermittent allergic rhinitis ( IAR ) persistent allergic rhinitis ( PER ) diagnose confirmatively definition current ARIA ( Allergic Rhinitis Impact Asthma ) guideline come effective Chinese allergic rhinitis management guideline . Subjects assess nasal symptom score compliance dairy card confirm whether meet randomization criterion . During treatment period , subject randomize ( 1 1 ratio ) FFNS 110ug match vehicle placebo nasal spray self administer intranasal treatment daily 2 week . Subjects rate nasal symptom score also document study drug administration compliance , medication condition experience , concomitant medication take dairy card . Subjects also assess severity overall interference activity diary living ( ADL ) baseline end study treatment questionnaire . At baseline end study treatment , investigator rate nasal finding score rhinoscopy , record patient note . A follow telephone contact make 3 5 day completion study treatment/early withdrawal ass post treatment adverse effect . The primary endpoint change baseline reflective total nasal symptom score ( rTNSS ) treatment period , secondary endpoint include completion study treatment , mean change baseline nasal find score rhinoscopy , severity overall inference activity daily live . The safety measure include ECGs , vital exam , physical exam , AE report . In addition , reflective total ocular symptom score ( rTOSS ) measure explorative endpoint , specific AR patient severe ocular symptom .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects enrol meeting criterion . 1 . Chinese adolescent adult ( male eligible female ) outpatients age &gt; =12 year 2 . Confirmative diagnosis IAR PER ( definition ARIA 2008 come effective Chinese AR management guideline ) , medical history , symptom , skin prick test ( SPTs ) 3 . Subject must symptomatic screen willing maintain environment throughout study 4 . Ability comply study procedures 5 . Literate Subjects exclude meet one criterion . 1 . Having complication nasal disease , vasomotor rhinitis , rhinitis eosinophilia , drug rhinitis 2 . Having complication bacterial/viral infection upper respiratory tract 3 . Having significant systemic disease 4 . History hypersensitivity steroid ingredient 5 . Pregnant woman lactation 6 . Patients start , discontinue change dose desensitization therapy within 30 day visit 1 7 . Patients plan travel outside region 8 . Patients judged inappropriate investigator 9 . Patients participate another study within 4 month screen 10 . Patients could withdraw drug screen period secure withdrawal period initiation day administration , e.g . 1. allergy medication 2. medication may affect allergic rhinitis symptom 3. medication significantly inhibit CYP3A4 , include ritonavir ketoconazole</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>placebo</keyword>
	<keyword>allergic rhinitis</keyword>
	<keyword>fluticasone furoate</keyword>
</DOC>